Theme 6 Genotypic resistance tests for the management of patients at simplification of highly active antiretroviral therapy

References

• Van Roon E, Verzijl J, Juttmann J, Lenderink A, Blans M, Egberts A. Incidence of discontinuation of highly active antiretroviral combination therapy (HAART) and its determinants. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20: 290–4.
   PubMedGoogle Scholar
• Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51–8.
   Google Scholar
• Carr A, Samaras K, Thorisdottir A, Kaufmann G, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipi- daemia, and diabetes mellitus: a cohort study. Lancet 1999; 353: 2093–9.
   PubMed Web of Science ®Google Scholar
• Lo J, Mulligan K, Tai V, Algren H, Schambelan M. Buffalo hump’ in men with HIV-1 infection. Lancet 1998; 351: 867–70.
   PubMed Web of Science ®Google Scholar
• Herry I, Bernard L, de Truchis P, Perrone C. Hypertrophy of the breasts in a patient treated with indinavir. Clin Infect Dis 1997; 25: 937–8.
   PubMed Web of Science ®Google Scholar
• Viraben R, Aquilina C. Indinavir-associated lipodystrophy. AIDS 1998; 12: F37–9.
   PubMed Web of Science ®Google Scholar
• Miller K, Jones E, Yanovski J, Shankar R, Fuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with the use of indinavir. Lancet 1998; 351: 871–5.
   PubMed Web of Science ®Google Scholar
• Havlir D, Marschner I, Hirsch M, Collier AC, Tebas P, Bassett RL, et al. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV-RNA after triple drug therapy. N Engl J Med 1998; 339: 1261–8.
   PubMed Web of Science ®Google Scholar
• Pialoux G, Raffi F, Brun-Vezinet F, Meiffredy V, Flandre P, Gastant JA, et al. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine and indinavir in previously untreated HIV-1 infected patients. N Engl J Med 1998; 339: 1269–75.
   Google Scholar
• Reijers M, Weverling G, Jurriaans S, Wit FW, Weigel HM, Ten Kate RW, et al. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet 1998; 352: 185–90.
   Google Scholar
• Barreiro P, Soriano V, Blanco F, Casimiro C, de la Cruz JJ, Gonzalez-Lahos J. Risks and benefits of replacing protease inhibitors by nevirapine in HIV infected subjects under longterm successful triple combination therapy. AIDS 2000; 14: 807–12.
   Google Scholar
• Hirschel B, Flepp M, Bucher H, Zellweger C, Telenti A, Wagels T, et al. Switching from protease inhibitors to efavirenz: differences in efficacy and tolerance among risk groups: a case control study from the Swiss HIV cohort. AIDS 2002; 16: 381–5.
   PubMed Web of Science ®Google Scholar
• Negredo E, Cruiz L, Paredes R, Ruiz L, Fumaz CR, Bonjoch A, et al. Virological, immunological and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and longlasting viral suppression. Clin Infect Dis 2002; 34: 504–10.
   PubMed Web of Science ®Google Scholar
• Maggiolo F, Migliorino M, Maserati R, Gregis G, Quinzan G, Ripamonti D, et al. Simplified therapeutic strategies in PI- experienced patients successfully treated with HAART. 41st ICAAC, Chicago, USA, December 2001. Abstract I–1916.
   Google Scholar
• Clumeck N, Goebel F, Rozenbaum W, Gerstof J, Staszewski S, Montaner J, et al., on behalf of the CNA 30017 Study Team. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1 infected patients with undetectable plasma HIV-1 RNA. AIDS 2001; 15: 1571–26.
   Google Scholar
• Opravil M, Hirschel B, Lazzarin A, Furrer H, Chave JP, Yerly S, et al., for the Swiss HIV Cohort Study. Simplified maintenance therapy with abacavir + lamivudine + zidovudine in patients with HAART-induced long-term suppression of HIV-1 RNA: final results. 40th ICAAC, Toronto, Canada, September 2000. Abstract 476.
   Google Scholar
• Koch N, Yahi N, Ariasi F, Fantini J, Tamalet C. Comparison of human immunodeficiency virus type 1 (HIV-1) protease mutations in HIV-1 genomes detected in plasma and in peripheral blood mononuclear cells from patients receiving combination drug therapy. J Clin Microbiol 1999; 37: 1595–7.
   Google Scholar
• Smith MS, Koerber KL, Pagano JS. Zidovudine-resistant human immunodeficiency virus type 1 genomes detected in plasma distinct from viral genomes in peripheral blood mononuclear cells. J Infect Dis 1993; 167: 445–8.
   Google Scholar
• Maggiolo F, Callegaro A, Arosio M, Gregis GP, Quinzan GP, Ripamonti D, et al. Rapid clearance of M184V mutation from proviral DNA allows drug recycling in salvage therapy. Antivir Ther 2001; 6: S20.
   Google Scholar
• Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 2001; 15: 1369–77.
   Google Scholar
• Maggiolo F. Comparison of NNRTIs in antiretroviral-experienced patients. Int J STD AIDS 2001; 12(4): 10–7.
   Google Scholar
• Martinez E, Podzamczer D, Ribera E, Domingo P, Knobel H, Dalmau D, et al. Switching protease inhibitors to nevirapine, efavirenz or abacavir: a randomized, multicenter, open-label, simplification trial. 9th Conference on Retroviruses and Opportunistic Infections, Chicago, USA, 2002. Abstract LB17.
   Google Scholar
• Casado JL, Arrizabalaga J, Moreno A, Iribarren JA, Munoz V, Antela A, et al. Maintenance therapy with non-nucleoside reverse transcriptase inhibitors for HIB-infected patients with intolerance to a successful protease inhibitor-containing regimen (BEGIN study): efficacy and resistance data. 40th ICAAC, Toronto, Canada, 2000. p. 326.
   Google Scholar